On March 16, 2023 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, reported that an abstract on its preclinical programs, ATRN-119 and ATRN-W1051, has been selected for presentation as a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2023 Annual Meeting, being held April 14-19, 2023, in Orlando, Florida (Press release, Aprea, MAR 16, 2023, View Source [SID1234628888]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentation are as follows:

Poster Title: ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment
Date & Time: Wednesday, April 19, 2023 at 9:00 am ET
Session Category & Title: Experimental and Molecular Therapeutics – DNA Damage Response